Zhong Guo Jing Ji Wang·2025-08-15 03:12Core Viewpoint - Junshi Bioscience (688180.SH) announced a share reduction plan by a major shareholder, Shanghai Tanying Investment Partnership, which holds 6.96% of the company's shares [1] Shareholder Reduction Plan - Shanghai Tanying plans to reduce its holdings by up to 20,533,797 shares, representing no more than 2% of the total share capital, through block trading [1] - The shares to be reduced were acquired before the company's IPO and became tradable on July 15, 2021 [1] - The reduction is due to the fund's liquidity arrangements and is compliant with specific regulations for venture capital fund shareholders [1][2] Shareholding Structure - As of the announcement, the total shares held by Shanghai Tanying and its related entities amount to 87,217,999 shares, or 8.4951% of the total [3] - Other entities controlled by Lin Lijun, such as Loyal Valley Capital Advantage Fund II LP and LVC Renaissance Fund LP, hold additional shares [2][3] Recent Share Reduction Activity - From October 23 to November 12, 2024, Shanghai Tanying and Shanghai Tanjing Investment Partnership reduced their holdings by 7,392,674 shares, equating to a 0.75% reduction, with a total transaction value of approximately 230 million yuan [4] Company Financials - Junshi Bioscience went public on July 15, 2020, with an initial offering of 87.13 million shares at a price of 55.50 yuan per share, raising a total of 4.836 billion yuan [5][6] - The company has faced significant financial losses, with net profits attributable to shareholders from 2016 to 2024 showing a consistent decline, reaching -2.283 billion yuan in 2024 [8]